Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Decide whether points or cash back is better for your travel needs. Explore the benefits of each to optimize your rewards strategy.
27,012 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
A new pediatric guidance warns that american schools have been quietly cutting recess in pursuit of test scores, risk...
Salesforce’s AI roadmap has captivated many, but the stock has faced a steep pullback. This article weighs the bulls’...
A seasoned advisor makes a bold move, unloading nearly $5 million in value stocks and doubling down on a market-timin...
A famous hair moment can teach practical money lessons. This article breaks down how to translate a premium makeover ...
U.S. stocks drift as a slate of fresh analyst calls prompts traders to reassess positions in consumer, tech and indus...
Vietnam and the Philippines have been upgraded to upper-middle-income status, signaling a new growth phase and bringi...
A widening trust gap is pushing American workers into siloed teams and news feeds. Executives are racing to rebuild d...
As the Fed's path becomes less predictable, investors weigh how many rate cuts to expect in 2026. This guide breaks d...
As 2026 unfolds, I’m leaning into one magnificent ETF that fits my high-conviction approach. Here’s why this fund sta...
Inflation remains a stubborn backdrop, yet stocks are pushing higher. This article breaks down what’s driving the ral...
Pipelines may not grab headlines, but their steady cash flow powers dividends for investors who plan ahead. Learn how...